GOVX on Nasdaq

GeoVax Labs, Inc.

American pharmaceutical preparations company based in Smyrna, active since 20082

In its 2026 annual report the company says: “GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The Company’s lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers.”4 Its shares trade on Nasdaq under the symbol GOVX.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with Elicio Therapeutics, Inc., Traws Pharma, Inc. or Apricus Biosciences, or pick any stock.

  • TickerGOVX on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersSmyrna, United States2
  • Incorporated inDE3
  • Business address1955 Lake Park Drive, Suite 300, Smyrna, Ga3
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KXK8Z4UZ4J7S862
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 45428962

See how the biggest companies compare on our leaderboards

GeoVax Labs, Inc. (“GeoVax”, “us”, “we” or the “Company”) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-869.3%Operating margin5
-862.3%Net margin5
-37.1%Revenue growth, 20255
-561.2%Return on equity5
-$21.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$18.1M

Out of $2.5M in revenue.56 The company lost money this year.

Financial statements

Revenue78910115$2.5M in 2025+112% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $1.2M$1.2M20192020: $1.8M$1.8M2020+55%2021: $385.5K$385.5K2021−79%2022: $81.5K$81.5K2022−79%2023: $0$020232024: $4.0M$4.0M20242025: $2.5M$2.5M2025−37%
Operating income78910115-$21.6M in 2025+812% since 2019
-$30.0M-$20.0M-$10.0M02019: -$2.4M-$2.4M20192020: -$2.8M-$2.8M2020+19%2021: -$18.7M-$18.7M2021+565%2022: -$14.0M-$14.0M2022−25%2023: -$26.7M-$26.7M2023+91%2024: -$25.1M-$25.1M2024−6%2025: -$21.6M-$21.6M2025−14%
Net income78910115-$21.5M in 2025+805% since 2019
-$30.0M-$20.0M-$10.0M02019: -$2.4M-$2.4M20192020: -$3.0M-$3.0M2020+25%2021: -$18.6M-$18.6M2021+528%2022: -$14.0M-$14.0M2022−24%2023: -$26.0M-$26.0M2023+85%2024: -$25.0M-$25.0M2024−4%2025: -$21.5M-$21.5M2025−14%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue from government contract$2.5M$4.0M
Research and development$18.1M$23.7M
General and administrative$6.0M$5.4M
Total operating expenses$24.1M$29.1M
Loss from operations-$21.6M-$25.1M
Interest income$174.3K$173.4K
Interest expense$0$21.4K
Total other income (expense)$174.3K$152.0K
Net loss-$21.5M-$25.0M
Net loss per common share (in dollars per share)-$22.40-$120.46
Weighted average shares outstanding (in shares)958.4K shares207.5K shares

Compare GeoVax Labs, Inc. with another company

Corporate structure

GeoVax Labs, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of GeoVax Labs, Inc.

  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on GeoVax Labs, Inc., latest Aug 14, 2026 (8 filings since Feb 14, 2024)
  • Ayrton Capital LLC Filed SCHEDULE 13G/A on GeoVax Labs, Inc., latest Aug 13, 2026 (2 filings since Feb 11, 2026)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on GeoVax Labs, Inc., latest Aug 13, 2026 (5 filings since Jul 8, 2025)
  • JANE STREET GROUP, LLC Filed SCHEDULE 13G/A on GeoVax Labs, Inc., latest Aug 10, 2026 (2 filings since Jun 9, 2026)
  • L1 Capital Global Opportunities Master Fund, Ltd. Filed SCHEDULE 13G/A on GeoVax Labs, Inc., latest Feb 17, 2026 (3 filings since Feb 14, 2022)
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on GeoVax Labs, Inc., latest Jan 5, 2022
  • GeoVax Labs, Inc. Smyrna, Georgia, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What GeoVax Labs, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$512.4K5 Dec 31, 2025$911.0K5 Dec 31, 2024−43.8%
Accumulated depreciation$403.6K5 Dec 31, 2025$761.0K5 Dec 31, 2024−47.0%
Property and equipment, net$108.8K5 Dec 31, 2025$150.0K5 Dec 31, 2024−27.4%
Operating-lease assets (leased space)$831.4K5 Dec 31, 2025$05 Dec 31, 2024

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$3.1M5 Dec 31, 2025$5.5M5 Dec 31, 2024−44.0%

Properties, in its own words

Our principal executive offices are located in Smyrna, Georgia, where we lease approximately 7,500 square feet of office space. Our lease for the premises is currently scheduled to terminate on October 31, 2028. Our laboratory operations are located in Atlanta, Georgia, where we lease wet lab space and associated office space. We do not currently own any real property. We believe that our current facilities are adequate to meet our immediate needs and that if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.

Item 2 of the 10-K filed Apr 15, 2026.4

Leadership

Who has led GeoVax Labs, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Donald G. Hildebrand2006–2007
  2. Robert T. McNally2008–2017
  3. David A. Dodd2018–now

President

  1. Donald G. Hildebrand2006–2007
  2. Robert T. McNally2008–2017
  3. David A. Dodd2018–now

Chief financial officer

  1. Mark Reynolds2006–now
2010201520202025
Board members and other officers (20)

Former names

  • DAUPHIN TECHNOLOGY INCAug 13, 1996 to Sep 20, 20063

Timeline

  1. Sep 10, 20268-K Other events34
  2. Aug 28, 20268-K Entered a material agreement; Unregistered sale of shares35
  3. Aug 28, 20268-K Listing notice or transfer36
  4. Jul 27, 20268-K Results of operations37
  5. Jul 10, 20268-K Listing notice or transfer38
  6. Jun 17, 20268-K Shareholder vote39
  7. May 19, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure40
  8. May 14, 20268-K Results of operations41
  9. May 7, 20268-K Entered a material agreement; Unregistered sale of shares42
  10. Apr 15, 20268-K Results of operations43
  11. Mar 31, 20268-K Entered a material agreement; Unregistered sale of shares44
  12. Feb 17, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure45
  13. Sep 5, 2018New chief executive David A. Dodd becomes CEO13
  14. Jun 19, 2008New chief executive Robert T. McNally becomes CEO14
  15. Jun 17, 2008Founded GeoVax Labs, Inc. is founded2
  16. Oct 10, 2006New chief executive Donald G. Hildebrand becomes CEO15

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($7.75) a share, on Nov 13, 2025.46

When it reported results

  1. Jul 27, 2026Reported quarterly or annual results37
  2. May 14, 2026Reported quarterly or annual results41
  3. Apr 15, 2026Reported quarterly or annual results43
  4. Nov 13, 2025Reported quarterly or annual results47
  5. Jul 29, 2025Reported quarterly or annual results48
  6. May 1, 2025Reported quarterly or annual results49
  7. Mar 28, 2025Reported quarterly or annual results50
  8. Nov 13, 2024Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

382 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 71 major events, 76 insider forms, 21 large holders, 2 private raises, 189 other. The latest 20:

  1. Sep 23, 2026EFFECT EDGAR
  2. Sep 17, 2026S-1 EDGAR
  3. Sep 10, 2026DEF 14A EDGAR
  4. Sep 10, 20268-K EDGAR
  5. Aug 31, 2026PRE 14A EDGAR
  6. Aug 28, 20268-K EDGAR
  7. Aug 28, 20268-K EDGAR
  8. Aug 14, 2026SCHEDULE 13G/A EDGAR
  9. Aug 13, 2026SCHEDULE 13G/A EDGAR
  10. Aug 13, 2026SCHEDULE 13G/A EDGAR
  11. Aug 10, 2026SCHEDULE 13G/A EDGAR
  12. Jul 27, 202610-Q EDGAR
  13. Jul 27, 20268-K EDGAR
  14. Jul 10, 20268-K EDGAR
  15. Jun 22, 20264 EDGAR
  16. Jun 22, 20264 EDGAR
  17. Jun 22, 20264 EDGAR
  18. Jun 22, 20264 EDGAR
  19. Jun 22, 20264 EDGAR
  20. Jun 22, 20264 EDGAR

The 382 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

22 open-market trades by officers, directors and large owners since October 2021: 22 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 17, 2025SPENCER JOHN N JRDirectorBuy10,000$0.55$5.5KForm 4
Aug 7, 2025McKee Kelly T. Jr.Chief Medical OfficerBuy1,107$0.67$742Form 4
Apr 10, 2025SPENCER JOHN N JRDirectorBuy10,000$0.98$9.8KForm 4
Apr 10, 2025Sharkey John W.VP, Business DevelopmentBuy6,000$0.99$5.9KForm 4
Apr 1, 2025DODD DAVID APresident, CEOBuy10,000$1.08$10.8KForm 4
Mar 31, 2025Reynolds MarkCFOBuy6,800$1.08$7.3KForm 4
Aug 9, 2024DODD DAVID APresident, CEOBuy8,000$1.95$15.6KForm 4
Feb 22, 2024DODD DAVID APresident, CEOBuy8,209$2.27$18.6KForm 4
Feb 21, 2024DODD DAVID APresident, CEOBuy520$2.15$1.1KForm 4
Feb 7, 2024Reynolds MarkCFOBuy2,000$2.77$5.5KForm 4
Dec 22, 2023McKee Kelly T. Jr.Chief Medical OfficerBuy6,944$0.36$2.5KForm 4
Sep 25, 2023McKee Kelly T. Jr.Chief Medical OfficerBuy9,653$0.52$5.0KForm 4
Aug 25, 2023DODD DAVID APresident, CEOBuy35,087$0.57$20.0KForm 4
Aug 18, 2023Reynolds MarkCFOBuy10,000$0.52$5.2KForm 4
Apr 24, 2023DODD DAVID APresident, CEOBuy32,000$0.64$20.5KForm 4
Apr 20, 2023Reynolds MarkCFOBuy8,000$0.63$5.0KForm 4
Sep 21, 2022CHASE RANDAL DDirectorBuy10,000$1.10$11.0KForm 4
Jul 1, 2022Sharkey John W.VP, Business DevelopmentBuy1,000$0.82$820Form 4
Jun 27, 2022McKee Kelly T. Jr.Chief Medical OfficerBuy4,464$1.12$5.0KForm 4
Jun 21, 2022CHASE RANDAL DDirectorBuy10,000$1.21$12.1KForm 4

All 22 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. May 25, 2022Raised $15 million in a private offering of equity Form D: 1 investor so far Form D
  2. Jan 19, 2022Raised $10 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC315,275$400.4K0.0%New
Geode Capital Management, LLC21,112$26.8K0.0%−14,964
Two Sigma Securities, LLC10,682$13.6K0.0%New
Vanguard Fiduciary Trust Co5,068$6.4K0.0%No change
Tower Research Capital LLC (TRC)3,502$4.4K0.0%−25
Vanguard Capital Management LLC3,217$4.1K0.0%No change
SBI Securities Co., Ltd.2,588$3.3K0.0%+2,204
Morgan Stanley2,003$2.5K0.0%+1,997
Jones Financial Companies Lllp1,000$1.3K0.0%New
UBS Group AG944$1.2K0.0%−3,304
BlackRock, Inc.842$1.1K0.0%−251
Citigroup Inc230$2920.0%New
Hrt Financial LP126,704$1600.0%New
Wells Fargo & Company/mn30$380.0%−1
Danske Bank A/s3$40.0%No change
Fmr LLC1$10.0%No change
Royal Bank Of Canada1$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How GeoVax Labs, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGeoVax Labs, Inc.1
  • CIK0000832489
  • Employer ID (EIN)87-04550384
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1955 Lake Park Drive, Suite 300, Smyrna, GA1
  • Phone678-384-72201
  • Shares outstanding7,369,243 as of Jul 27, 202612
  • Public float$13.7M as of Jun 30, 20254
  • AuditorWIPFLI LLP, Atlanta, Georgia PCAOB ID 344; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 13, 19961
  • Filings1,180 in all: 4 (251), 8-K (246), 424B3 (108), 10-Q (84), EFFECT (54), POS AM (38), CORRESP (35), DEF 14A (30)1
    All 51 form types

    10-K (28), UPLOAD (27), S-1 (26), SC 13G/A (25), S-1/A (24), 3 (20), PRE 14A (19), 424B1 (17), 424B5 (14), SCHEDULE 13G/A (12), D (11), SC 13G (11), 10-Q/A (10), DEFA14A (10), 10-K/A (8), SC 13D/A (7), 8-K/A (6), POS EX (6), NT 10-K (5), SCHEDULE 13G (5), 4/A (4), 424B4 (3), AW (3), NT 10-Q (3), PRER14A (3), S-3 (3), SC 13D (3), D/A (2), DRS (2), PRER14C (2), RW (2), S-8 (2), 25-NSE (1), 5 (1), 8-A12B (1), 8-A12G (1), CERT (1), DEF 14C (1), DEFR14A (1), DRSLTR (1), PRE 14C (1), REGDEX/A (1), S-1MEF (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Jul 27, 2026
    Proxy statement (DEF 14A) Sep 10, 2026
    Latest 8-K (8-K) Sep 10, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock $0.001 par valueGOVXNasdaq

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks GeoVax Labs, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 34 risks under these headings, as written.4

  • Risks Related to Our Business and Capital Requirements
  • We have a history of operating losses, and we expect losses to continue for the foreseeable future.
  • We have received a going concern opinion from our auditors.
  • Our business will require continued funding. If we do not receive adequate funding, we may not be able to continue our operations.
  • Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business.
  • Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties
  • Our products are still being developed and are unproven. These products may not be successful.
  • We depend upon key personnel who may terminate their employment with us at any time. If we were to lose the services of any of these individuals, our business and operations may be adversely affected.
  • Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.
  • We face intense competition and rapid technological change that could result in products that are superior to, or earlier to the market than, the products we will be commercializing or developing.
  • Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.
  • We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.
The other 23 risks
  • Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.
  • State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.
  • Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.
  • We may not be successful in establishing collaborations for product candidates we seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.
  • We do not have manufacturing, sales or marketing experience.
  • Our products under development may not gain market acceptance.
  • We may be required to defend lawsuits or pay damages for product liability claims.
  • Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used.
  • Risks Related to Our Intellectual Property
  • Our success depends on our ability to obtain, maintain, protect, and enforce our intellectual property and our proprietary technologies.
  • We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.
  • Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products.
  • Any inability to protect our or our licensors’ intellectual property rights in the United States and foreign countries could limit our ability to prevent others from manufacturing or selling our products.
  • Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
  • The patent protection and patent prosecution for our product candidates is dependent in part on third parties.
  • Changes to the Biologics Price Competition and Innovation Act’s exclusivity provisions could affect our market exclusivity.
  • Risks Related to Our Securities
  • The market price of our Common Stock is highly volatile.
  • The sale or issuance of additional shares of our Common Stock or other equity securities could result in additional dilution to our stockholders.
  • Certain provisions of our certificate of incorporation which authorize the issuance of shares of preferred stock may make it more difficult for a third party to effect a change in control.
  • We have never paid dividends and have no plans to do so.
  • Public company compliance may make it more difficult for us to attract and retain officers and directors.
  • Our Certificate of Incorporation and Bylaws may be amended by the affirmative vote of a majority of our stockholders.
  • Broker-dealers may be discouraged from effecting transactions in shares of our Common Stock if we are considered to be a penny stock and thus subject to the penny stock rules.
  • Our common stock currently is listed for quotation on the Nasdaq Capital Market. We are required to meet specified financial requirements in order to maintain such listing, including a requirement that the bid price for our common stock remain above $1.00, and that the market value of our publicly held securities be at least $1 million. In addition, Nasdaq has recently proposed a new $5 million market value of listed securities requirement that we would not currently satisfy and therefore could cause our common stock be delisted by Nasdaq on an imminent basis, if approved by the SEC.

Legal proceedings

We are not currently a party to any material legal proceedings. We may from time to time become involved in various legal proceedings such as those arising in the ordinary course of business.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57